Global X Aging Population ETF

AGNG

Valor de mercado US$ 90,9 mi

With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.

Longevity is, increasingly, a big business. Advances in healthcare technology and AI have prompted both prominent medical professionals and individual investors to imagine how people might live longer, healthier lives.

ETFs like XLV stand out as aging U.S. demographics fuel rising demand for healthcare, medical devices and senior-focused care.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Healthcare stocks started the year off very strongly as investors cheered the sector's advances. Among the sector's catalysts have been continued, strong enthusiasm for a new class of weight-loss drugs called GLP-1 and Nvidia's decision, disclosed earlier this month, to invest in a medical imaging company and a firm that uses artificial intelligence ( AI ) to speed up the drug discovery process.